Hugon, Jacques

Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.

Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 638

Phosphorylation of eukaryotic initiation factor-2α (eIF2α) is associated with neuronal degeneration in Alzheimerʼs disease

Chang, R. C. C., Wong, A. K. Y., Ng, H.-K., & Hugon, J. (2002) · NeuroReport

Alzheimer's disease research and treatmentsEndoplasmic Reticulum Stress and Disease

Cited by 289

mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP‐PS1 transgenic models and in patients with Alzheimer's disease

Lafay‐Chebassier, C., Paccalin, M., Page, G., Barc‐Pain, S., Perault‐Pochat, M. C., Gil, R., Pradier, L., & Hugon, J. (2005) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 211

mTOR‐dependent signalling in Alzheimer's disease

Pei, J., & Hugon, J. (2008) · Journal of Cellular and Molecular Medicine

Alzheimer's disease research and treatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 190

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 184

Involvement of double‐stranded RNA‐dependent protein kinase and phosphorylation of eukaryotic initiation factor‐2α in neuronal degeneration

Chang, R. C., Suen, K., Ma, C., Elyaman, W., Ng, H., & Hugon, J. (2002) · Journal of Neurochemistry

Endoplasmic Reticulum Stress and DiseaseAlzheimer's disease research and treatments

Cited by 180

Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls

Bellenguez, C., Charbonnier, C., Grenier-Boley, B., Quenez, O., Le Guennec, K., Nicolas, G., Chauhan, G., Wallon, D., Rousseau, S., Richard, A. C., et al. (2017) · Neurobiology of Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 166

SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease

Nicolas, G., Charbonnier, C., Wallon, D., Quenez, O., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., Le Guennec, K., et al. (2016) · Molecular Psychiatry

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 129

Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer’s disease

Page, G., Rioux Bilan, A., Ingrand, S., Lafay-Chebassier, C., Pain, S., Perault Pochat, M. C., Bouras, C., Bayer, T., & Hugon, J. (2006) · Neuroscience

Alzheimer's disease research and treatmentsEndoplasmic Reticulum Stress and Disease

Cited by 116

Biomarkers in Sporadic and Familial Alzheimer’s Disease

Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 106

Activated mTOR and PKR Kinases in Lymphocytes Correlate with Memory and Cognitive Decline in Alzheimer’s Disease

Paccalin, M., Pain-Barc, S., Pluchon, C., Paul, C., Besson, M.-N., Carret-Rebillat, A.-S., Rioux-Bilan, A., Gil, R., & Hugon, J. (2006) · Dementia and Geriatric Cognitive Disorders

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 96

Upstream Signaling Pathways Leading to the Activation of Double-stranded RNA-dependent Serine/Threonine Protein Kinase in β-Amyloid Peptide Neurotoxicity

Suen, K.-C., Yu, M.-S., So, K.-F., Chang, R. C.-C., & Hugon, J. (2003) · Journal of Biological Chemistry

Alzheimer's disease research and treatmentsEndoplasmic Reticulum Stress and Disease

Cited by 95

ABCA7 rare variants and Alzheimer disease risk

Le Guennec, K., Nicolas, G., Quenez, O., Charbonnier, C., Wallon, D., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., et al. (2016) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 69

PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease

Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 64

The immunosuppressant rapamycin exacerbates neurotoxicity of Aβ peptide

Lafay‐Chebassier, C., Pérault‐Pochat, M. C., Page, G., Bilan, A. R., Damjanac, M., Pain, S., Houeto, J., Gil, R., & Hugon, J. (2006) · Journal of Neuroscience Research

Alzheimer's disease research and treatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 52

Effect of active A β immunotherapy on neurons in human Alzheimer's disease

Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 44

Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer’s disease

Damjanac, M., Rioux Bilan, A., Paccalin, M., Pontcharraud, R., Fauconneau, B., Hugon, J., & Page, G. (2008) · Neurobiology of Disease

Alzheimer's disease research and treatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 32

PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients

Damjanac, M., Page, G., Ragot, S., Laborie, G., Gil, R., Hugon, J., & Paccalin, M. (2009) · Journal of Cellular and Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 31

Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer’s Disease Diagnosis in Cognitively Impaired Patients

Lilamand, M., Bouaziz-Amar, E., Dumurgier, J., Cognat, E., Hourregue, C., Mouton-Liger, F., Sanchez, M., Troussière, A.-C., Martinet, M., Hugon, J., et al. (2023) · The Journals of Gerontology: Series A

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 27

Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review

Gaubert, S., Hourregue, C., Mouton-Liger, F., Millot, P., Franco, M., Amar-Bouaziz, E., Aarsland, D., Hugon, J., & Paquet, C. (2022) · Neuroscience & Biobehavioral Reviews

Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments

Cited by 26